+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of TQB2102 for injection compared to a standard drug regimen in the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. This phase III randomized, open-label, multi-center trial involves about 544 patients who will be assigned to receive either TQB2102 or a combination of Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin. The study aims to assess key outcomes such as total physiological complete response tpCR, breast pathological complete response bpCR, objective response rate ORR, event-free survival EFS, invasive disease-free survival IDFS, overall survival OS, and safety indicators including adverse events and immune response markers. Participants in the TQB2102 group will receive 8 cycles of intravenous infusion every 3 weeks, each cycle lasting 21 days. The comparator group will receive 6 cycles of a combination treatment with Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin, also administered intravenously every 3 weeks for 21-day cycles. After completing the assigned treatment cycles, all participants will undergo breast cancer surgery. Following surgery, there will be visits to monitor disease recurrence and overall survival. Throughout the study, participants will be closely monitored with evaluations conducted up to 50 months after study start. These include assessments of tumor response by independent review and investigators, safety monitoring from consent through 40 days post last dosing or surgery, and testing for anti-drug and neutralizing antibodies. Participants will have scheduled visits for treatment administration, surgery, and follow-up to track outcomes and safety over several years.

Age: 18Years - 75YearsAll GendersPhase 3
77 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of ATG-022 compared to Investigators Choice treatment in participants with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma who have received prior second-line systemic therapy. This Phase III, randomized, controlled, open-label study involves participants with unresectable locally advanced or metastatic disease who have progressed after at least second-line and no more than fourth-line systemic therapy. The study is based on positive earlier data and aims to compare ATG-022 monotherapy with commonly used chemotherapy options. Participants receive either ATG-022 monotherapy at a dose of 1.8 mgkg every 21 days one cycle or Investigators Choice chemotherapy, which includes either Docetaxel or Irinotecan. Docetaxel is administered at 75-100 mgm every 21 days, while Irinotecan is given at 125 mgm on days 1 and 8 every 21 days. The study uses a parallel design to compare these two treatment regimens. Throughout the trial, participants undergo tumor assessments at baseline and then every 6 weeks during treatment, followed by less frequent evaluations after 12 and 24 months until disease progression or death. Survival follow-up occurs every 3 months until death or study end. Researchers measure progression-free survival, overall survival, objective response rate, disease control rate, and duration of response. Laboratory tests and physical examinations are conducted to monitor organ function and safety. Participants remain in the study until disease progression, death, or study completion, with ongoing monitoring of their health.

Age: 18Years +All GendersPhase 3
131 locations
P

Actively Recruiting

Researchers are evaluating the preliminary effectiveness of TQB2825 combined with chemotherapy in adults with diffuse large B-cell lymphoma that has returned or not responded to previous treatments. This phase II clinical trial focuses on patients who have relapsed or refractory disease and are not suitable for stem cell transplantation, aiming to understand how well this combination works in this group. Participants receive a combination treatment that includes TQB2825 injection, gemcitabine hydrochloride for injection, and oxaliplatin for injection. The treatment cycles last 21 days, with careful monitoring of drug levels and response. The study measures various outcomes such as complete response rate after one year, overall survival up to three years, and other markers related to treatment effectiveness and safety. During the trial, participants undergo regular assessments including scans, laboratory tests, and evaluations of response and side effects. Researchers collect detailed pharmacokinetic data at specific time points during treatment cycles. The study also monitors the presence of anti-drug antibodies over two years. Participants health is observed throughout treatment and follow-up periods to evaluate both the response and safety of the therapy.

Age: 18Years +All GendersPhase 2
24 locations
P

Actively Recruiting

Researchers are evaluating the progression-free survival of D-1553 Tablet compared to Docetaxel Injection in patients with KRAS G12C mutation-positive locally advanced or metastatic non-small cell lung cancer NSCLC who have not responded to prior standard therapy. This phase III, randomized, controlled, double-blind study aims to assess progression-free survival as the primary endpoint, with other outcomes measured over up to three years. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Participants will receive either the experimental D-1553 Tablet or the active comparator Docetaxel Injection, each administered in 21-day treatment cycles. D-1553 is a KRAS inhibitor, while Docetaxel is an anti-tumor drug that works by affecting microtubule dynamics. The study design includes a quadruple masking and random allocation to ensure unbiased results. During the study, participants will undergo evaluations of progression-free survival, overall survival, response rates, disease control, and patient-reported outcomes over a period of up to three years. Safety assessments include monitoring adverse events and laboratory tests from consent through 30 days after the last dose. Pharmacokinetic parameters such as time to maximum plasma concentration and half-life will be measured during specific cycles. The total participation duration depends on individual treatment response and follow-up.

Age: 18Years +All GendersPhase 3
86 locations
E

Actively Recruiting

Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.

Age: 18Years +All GendersPhase 3
119 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of oral minocycline in patients who have experienced an acute spontaneous intracerebral hemorrhage within 48 hours of onset. This prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial aims to improve patient outcomes and explore the effects of minocycline on venous neuroinflammation in this condition. Participants will be randomly assigned to receive either minocycline or a matching placebo for 5 days alongside standard medical care. The minocycline group will take an initial dose of 200 mg immediately after randomization, followed by 100 mg every 12 hours for a total of 10 doses. Those with swallowing difficulties may receive the medication through a nasal feeding tube. The trial includes screening, treatment, and follow-up phases with visits scheduled at screening, 72 hours, 7 days, 90 days, and 180 days after randomization. During the study, participants will undergo assessments including neurological evaluations and imaging at specified time points. Researchers will measure outcomes such as the modified Rankin Scale score at 90 days, changes in neurological scores, inflammation markers, and stroke recurrence. Safety and efficacy will be monitored through these evaluations, with total participation lasting up to 180 days post-randomization.

Age: 18Years - 80YearsAll GendersPhase 3
41 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of Prunella oral liquid in adults with benign thyroid nodules. This phase 4, multicenter, randomized, double-blind, placebo-controlled trial aims to provide post-marketing reevaluation data on this treatment. Eligible participants have thyroid nodules confirmed benign by biopsy and normal thyroid hormone and antibody levels. The study includes 234 subjects recruited across multiple centers in China and focuses on changes in nodule volume and related health measures over time. Participants are randomly assigned to one of four groups receiving either a regular or double dose of Prunella oral liquid or a matching placebo at the same doses. Treatment lasts for 9 months, with follow-up visits scheduled at 3, 6, 9, and 12 months. Dosing is oral, twice daily, and the study includes monitoring for treatment effects and safety measures. During the study, participants undergo thyroid ultrasound examinations and blood tests to assess nodule size, thyroid function, antibody levels, and quality of life through questionnaires. Researchers track changes in nodule volume and diameter as primary and secondary outcomes, along with safety assessments such as adverse event monitoring and laboratory tests. The total participation duration spans up to 12 months, with thorough evaluations at specified intervals to understand treatment impact and safety.

Age: 18Years - 65YearsAll GendersPhase 4
22 locations
E

Actively Recruiting

Healthy Volunteer

Obesity greatly increases the risk of heart failure, and current treatments like caloric restriction, exercise, medications, or surgery may not be suitable for obese patients with heart failure. This research aims to study whether a combined approach using a diet management app and an intelligent weight scale can help obese patients with heart failure and reduced ejection fraction lose weight and improve their heart condition. The trial compares the effectiveness of a fully functional app and scale versus a limited-function version to assess their impact on heart failure outcomes and overall quality of life. Participants are randomly assigned to two groups one using a fully featured diet management app and intelligent weight scale with various monitoring tools and health metrics, and the other using a limited version of both. The full app tracks food intake, exercise, weight, and provides dietary analysis and recommendations, while the full scale measures body composition and vital signs. The limited versions offer fewer features. Participants use the app at every meal and weigh themselves daily for 12 months. During the study, participants will visit the clinic at 12 months for checkups. Researchers will evaluate outcomes such as a composite of death and heart failure hospitalizations over one year, changes in quality of life related to heart failure, and weight change. The trial includes monitoring of heart failure frailty and quality of life assessments at baseline, 3 months, and 1 year, with ongoing safety and condition tracking throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
26 locations
P

Actively Recruiting

Researchers are comparing the safety and effectiveness of TQB2450 injection combined with anlotinib and chemotherapy versus TQB2450 injection combined with chemotherapy alone in people with advanced non-small cell lung cancer NSCLC who have not responded to first-line chemotherapy combined with immunotherapy. The study also aims to explore biomarkers related to treatment effectiveness, mechanisms of action or resistance, and safety. This is a randomized, double-blind, phase II clinical trial conducted by Tianjin Medical University Cancer Institute and Hospital. Participants receive treatment every three weeks. One group receives TQB2450 1200 mg intravenously on day 1, anlotinib oral capsules on days 1 to 14, and docetaxel chemotherapy 60 mg per square meter intravenously on day 1. The other group receives TQB2450 and docetaxel chemotherapy with a placebo instead of anlotinib. Treatment is given in cycles of three weeks. During the study, participants will be monitored through various assessments including tumor measurements to evaluate progression-free survival up to 48 weeks. Other outcomes include overall response rate, disease control rate, overall survival, and duration of response. Safety and tolerability will be closely observed. The total duration of participation varies, with follow-up continuing until disease progression or death.

Age: 18Years - 75YearsAll GendersPhase 2
5 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of combining two drugs, iparomlimab and tuvonralimab QL1706, with chemotherapy to treat adults with HER2-negative, low PD-L1 expressing, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. This phase II trial focuses on patients whose cancer cannot be removed by surgery or has spread to other parts of the body. The study aims to understand how well this combination works and its safety profile in this specific group of patients. Participants will receive iparomlimab and tuvonralimab at a dose of 5 mgkg by intravenous drip on the first day of each 3-week cycle until disease progression or unacceptable side effects occur. They will also receive XELOX chemotherapy, which includes oxaliplatin given intravenously at 130 mgm2 on day 1 of each 3-week cycle for the first 6 cycles, and capecitabine tablets taken orally twice daily from days 1 to 14 of each cycle. This treatment continues until disease progression or intolerable toxicity. The study is a single-arm trial, meaning all participants receive this combination treatment. During the trial, researchers will monitor participants for progression-free survival over 12 months after the last participant joins, along with overall survival, response rates, duration of response, disease control rate, and safety through adverse event tracking for up to about 2 years. Participants will undergo regular assessments to measure tumor response and side effects. The total study period includes these follow-up evaluations to understand the treatments impact and safety profile comprehensively.

Age: 18Years - 75YearsAll GendersPhase 2
29 locations

1-10 of 14

1